Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cullinan Therapeutics director Andrew R. Allen received a grant of stock options covering 21,781 shares of common stock at an exercise price of $13.55 per share. These options vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, subject to his continued board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Allen Andrew R

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	21,781	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 21,781 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option shares granted: 21,781 shares Exercise price: $13.55 per share Total derivative holdings after grant: 21,781 options +1 more

4 metrics

Option shares granted 21,781 shares Stock option grant to director on June 16, 2026

Exercise price $13.55 per share Exercise price of granted stock options

Total derivative holdings after grant 21,781 options Total options held following the reported transaction

Vesting date Earlier of June 16, 2027 or next annual meeting Full vesting trigger for the stock option grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 13.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"which shall vest in full on the earlier of (i) June 16, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting financial

"or (ii) the date of the Issuer's next annual meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 05:01 PM Accepted by SEC EDGAR 06/18/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allen Andrew R

(Last)

(First)

(Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.55	06/16/2026		A		21,781		⁽¹⁾	06/16/2026	Common Stock	21,781	$0	21,781	D

Explanation of Responses:

1. The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) report on this Form 4?

Cullinan Therapeutics reported that director Andrew R. Allen received a grant of stock options for 21,781 shares of common stock. The options were awarded at a $13.55 exercise price and represent compensation rather than an open-market stock purchase or sale.

How many shares are covered by Andrew R. Allen’s new Cullinan Therapeutics (CGEM) stock options?

The option grant covers 21,781 shares of Cullinan Therapeutics common stock. This amount also equals his total derivative holdings following the transaction, indicating this award established his reported option position as of the transaction date in the filing.

What is the exercise price of the new Cullinan Therapeutics (CGEM) stock options?

The stock options granted to Andrew R. Allen carry an exercise price of $13.55 per share. This price is the cost per share he would pay to convert the options into common stock once they are vested and exercisable.

When do Andrew R. Allen’s Cullinan Therapeutics (CGEM) stock options vest?

The options vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting. Vesting is conditioned on his continued service as a director through the applicable vesting date specified in the grant terms.

Is Andrew R. Allen’s Cullinan Therapeutics (CGEM) option grant a market purchase or sale?

The Form 4 classifies this as a grant or award acquisition, not an open-market trade. The transaction code is “A,” indicating a compensatory award of stock options, so no market buy or sell of common shares occurred in this transaction.